Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
SHR-1210
The First People's Hospital of Lianyungang
Resectable Esophageal Squamous Cell Carcinoma
1 trial -
SHR-1210
Hospital Authority, Hong Kong
Renal Cell Carcinoma
1 trial -
SHR-1701
The First People's Hospital of Lianyungang
Gastric Adenocarcinoma
1 trial -
SHR-1701 Combined With Fluazopalil
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
1 trial -
SHR2554/AZA + Overlapped TBF
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
SI-B001
Sichuan Baili Pharmaceutical Co.,
Non Small Cell Lung Cancer
1 trial -
SIRT Yttrium-90
Chinese University of Hong Kong
Cholangio Carcinoma
1 trial -
SKB103 for injection monotherapy
Sichuan Provincial People's Hospital
Advanced Solid Tumors
1 trial -
SKB264-II-04
Lacuna Pharma Pty Ltd
Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
SMILE
Fondazione Telethon ETS
Subjects at high risk of inflammatory state and mortality from lung cancer, other cancers and all causes
1 trial -
SNDX-5613
Syndax Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
SNDX-5613-0700
Syndax Pharmaceuticals
Relapsed or Refractory Acute Leukemias
1 trial -
SNS-101 (anti-VISTA)
Regeneron UK Limited
Solid Tumor, Adult
1 trial -
SNS-301
Sensei Biotherapeutics
Squamous Cell Carcinoma of the Head and Neck
1 trial -
SOGUG2020IEC(VEJ)11
Tour Hekla
Muscle-invasive bladder cancer (MIBC)
1 trial -
SOLARIS
The George Institute
advanced stage hepatocellular carcinoma
1 trial -
SOTORASIB
Amgen
KRAS p.G12C Mutant Advanced Solid Tumors
1 trial -
SOTORASIB
Amgen
Non-small cell lung cancer (NSCLC)
1 trial -
SOX Chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastroesophageal Junction Adenocarcinoma
1 trial -
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Lacuna Pharma Pty Ltd
Hypercortisolism related to benign adrenal tumour
1 trial -
SPLFIO-174
The George Institute
Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC
1 trial -
SPON - 1751-19
Cardiff Oncology
Blood cancer
1 trial -
SRF388
Coherus Oncology
Hepatocellular Carcinoma
1 trial -
SRF617
Arcus Biosciences
Metastatic Castration-resistant Prostate Cancer
1 trial -
SSGJ-706+XELOX
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Gastric/Gastroesophageal Junction Adenocarcinoma
1 trial -
SSGJ-707
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
1 trial -
SSGJ-707
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Metastatic Colorectal Cancer
1 trial -
STC-15 in combination with toripalimab
Coherus Oncology
Solid Tumor
1 trial -
STML-ELA-0322
Stemline Therapeutics B.V.
metastatic breast cancer
1 trial -
STRO-002
SUTRO BIOPHARMA, INC.
Neoplasm Malignant
1 trial -
STRO-002-GM3
SUTRO BIOPHARMA, INC.
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)
1 trial -
SU2C-001
BRIGHT MINDS BIOSCIENCES INC.
Previously Treated Metastatic Pancreatic Cancer
1 trial -
SV-BR-1-GM
BriaCell Therapeutics
Breastcancer
1 trial -
SX-682
United Therapeutics Europe Ltd
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
1 trial -
SY-1425, AZACITIDINE
Lacuna Pharma Pty Ltd
Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)
1 trial -
SY-1425-202
Lacuna Pharma Pty Ltd
RARA-positive acute myeloid leukemia
1 trial -
SYSUCC-CMY-2022-0416
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Sacituzumab Tirumotecan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Extensive-Stage Small Cell Lung Cancer
1 trial -
Sacituzumab Tirumotecan and Limertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
EGFR-mutant Non-small Cell Lung Cancer
1 trial -
Sacituzumab Tirumotecan in combination with tislelizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Sacituzumab tirumotecan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
TNBC - Triple-Negative Breast Cancer
1 trial -
Safety and efficacy of IMM-101 combined with...
Disc Medicine
Limited metastatic pancreatic cancer
1 trial -
Sandwich stratergy
The First People's Hospital of Lianyungang
Acute Lymphobkastic Leukemia
1 trial -
Saruparib
AstraZeneca AB
Advanced/Recurrent Ovarian cancer
1 trial -
Sasanlimab Prefilled syringe
Pfizer
Carcinoma, Non-Small-Cell Lung
1 trial -
Sativex
Jazz Pharmaceuticals Ireland Limited
Cancer
2 trials -
Savolitinib
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Self-hypnotic Relaxation
United Therapeutics Europe Ltd
Breast Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.